<a href="https://laohu8.com/S/SBHMY">Sino Biopharmaceutical</a> Limited Reports 27.2% Increase in Innovative Product Sales and Significant Year-on-Year Profit Growth for First Half of 2025
Sino Biopharmaceutical Limited reported its results for the six months ended 30 June 2025. The company recorded revenue of RMB17.57 billion, reflecting an increase of 10.7% compared to the same period last year. Profit attributable to owners of the parent from continuing operations was RMB3.39 billion, representing an increase of 140.2% year-on-year. Basic earnings per share from continuing operations were RMB18.82 cents, up 145.7% from the prior-year period. Sales of innovative products reached RMB7.80 billion, an increase of 27.2% from RMB6.13 billion a year earlier, and accounted for 44.4% of total revenue, up from 38.6% previously. The board of directors declared an interim dividend of HK5 cents per share for the six months ended 30 June 2025. The company attributed the increase in profit to growth in revenue, higher dividend income, and fair value gains on investments during the period. Sino Biopharmaceutical's operations cover R&D, production, and sales, with products spanning therapeutic areas such as oncology, liver and metabolic diseases, respiratory, and surgery/analgesia.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.